Article and Video CATEGORIES
One of the current controversies in the field of lung cancer is whether we should be doing biopsies routinely when a patient develops progression of their disease, particularly in the setting of acquired resistance to a molecularly targeted therapy. There are some academic oncologists who favor this approach, but I think there's a very good reason why this isn't and shouldn't be the current standard of care.
[powerpress]
Agree or disagree? I'm interested in hearing opinions from those with the perspective of the patient or caregiver, as well as other physicians who might be involved in these decisions.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi amitchouhan,
Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...
I was searching for this, Thank you so much for the info.
Glad to help. FYI, I just edited the link, which has the agenda and links to oncologists' bios. Plus, the link is also on our home page, https://cancergrace.org/
Hope to see...